MAKING A COMMITMENT TO YOU AND YOUR PATIENTS
Ongoing trials
EFFISAYIL® ON
An open-label extension study to evaluate the long-term safety and efficacy of intravenous and subcutaneous spesolimab in patients with generalized pustular psoriasis (GPP) who have completed previous spesolimab trials1
Interim analysis presented at AAD 2026
EFFISAYIL® REP
An open-label, single-arm, Phase 4 trial to evaluate the efficacy, safety, and impact of immunogenicity in the treatment of patients with GPP presenting with a recurrent flare following their initial GPP flare treatment with intravenous spesolimab2
AAD, American Academy of Dermatology.